Basis: FMP quote market capitalization / revenue from four consecutive issuer fiscal quarters. Source: stored company filings and market data; unavailable inputs remain N/A.
The P/S ratio is N/A as of 2026-10-06T21:22:31.995Z.
Calculation as of: 2026-10-06T21:22:31.995Z.
Quote observation: 2026-10-06T20:00:00.000Z. Amounts in USD. The price header may show a later quote.
FMP input reference: 47811cd6fce140e68777d2609bf88a35ade871fb75fdb0cf4ca3c33c868081b2
Historical values estimate market capitalization from statement-period weighted shares. Comparisons with the current quote-based value are approximate. Only filing versions delivered by FMP are available for the historical calculation.
PS RATIO
N/A
Market Cap
$10.06M
PS Ratio
182.90
TTM Avg
604.36
3Y Avg
203.60
5Y Avg
133.69
Market Cap
$9.83M
PS Ratio
0.98
TTM Avg
3.60
3Y Avg
6.58
5Y Avg
46.05
| NAME | MARKET CAP | PS RATIO | TTM | 3Y | 5Y |
|---|---|---|---|---|---|
| Medicus Pharma Ltd. Common Stock (MDCX) | $10.06M | N/A | N/A | N/A | N/A |
| Senti Biosciences, Inc. (SNTI)vs › | $10.06M | 182.90 | 604.36 | 203.60 | 133.69 |
| Tvardi Therapeutics, Inc. (TVRD)vs › | $10.13M | N/A | 56.92 | 56.92 | 56.92 |
| Lifeward Ltd. (LFWD)vs › | $10.21M | 0.47 | 0.51 | 1.36 | 4.08 |
| Valion Bio, Inc. (VBIO)vs › | $9.86M | N/A | 91.76 | 49.38 | 97.49 |
| NeuroOne Medical Technologies Corporation (NMTC)vs › | $9.83M | 0.98 | 3.60 | 6.58 | 46.05 |
| MetaVia Inc. (MTVA)vs › | $9.75M | N/A | N/A | N/A | N/A |
| Satellos Bioscience Inc. (MSLE)vs › | $9.71M | N/A | N/A | N/A | N/A |
| Adial Pharmaceuticals, Inc. (ADIL)vs › | $10.45M | N/A | N/A | N/A | N/A |
| Ainos, Inc. (AIMD)vs › | $9.50M | 698.55 | 337.84 | 351.63 | 923.89 |
Trailing-12-month revenue adds these four fiscal quarters. Amounts are in USD, rounded only to whole currency units.
| Fiscal period | Revenue | Source |
|---|---|---|
| Q3 FY2025Period ended 2025-09-30 | $0 | Filing link unavailableFMP normalized income statementFiling date supplied by FMP: 2025-11-14 |
| Q4 FY2025Period ended 2025-12-31 | $0 | Filing link unavailableFMP normalized income statementFiling date supplied by FMP: 2026-03-25 |
| Q1 FY2026Period ended 2026-03-31 | $0 | Filing link unavailableFMP normalized income statementFiling date supplied by FMP: 2026-05-14 |
| Q2 FY2026Period ended 2026-06-30 | $0 | Filing link unavailableFMP normalized income statementFiling date supplied by FMP: 2026-08-12 |
| TTM revenue | $0 |
The current P/S calculation cannot be reconciled from the stored quote and revenue inputs.
These references are supplied through FMP. Full filing context identifiers and dimensional metadata are unavailable in the normalized feed.
P/S Ratio
N/A
Market Cap / Trailing Twelve-Month Revenue
PS Ratio = Market Cap / Revenue (TTM)
The price-to-sales ratio compares market capitalization to trailing revenue. It is useful for valuing companies with little or no earnings.
Expanded definitions: Investopedia, Wikipedia, Corporate Finance Institute
